Adjuvant endocrine therapy compared with no systemic therapy for elderly women with early breast cancer: 21-Year results of International Breast Cancer Study Group Trial IV

Diana Crivellari, Karen Price, Richard D. Gelber, Monica Castiglione-Gertsch, Carl Magnus Rudenstam, Jurij Lindtner, Martin F. Fey, Hans Jörg Senn, Alan S. Coates, John Collins, Aron Goldhirsch

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

Purpose: Increasing numbers of older women are affected by early breast cancer, because of prolonged life expectancy and the increasing incidence of breast cancer with age. The role of adjuvant therapy for this population is still a matter of debate. We reviewed the long-term outcome of a mature trial comparing endocrine treatment versus no adjuvant therapy in older women with node-positive breast cancer. Patients and Methods: From 1978 to 1981, 349 women 66 to 80 years of age with pathologically involved lymph nodes after total mastectomy and axillary clearance were randomly assigned to receive 12 months of adjuvant tamoxifen plus low-dose prednisone (p+T) or no adjuvant therapy. Three hundred twenty patients were eligible. Results: At 21 years' median follow-up, 1 year of p+T significantly prolonged disease-free survival (DFS; P = .003) and overall survival (P = .05; 15-year DFS, 10% ± 3% v 19% ± 3%; hazard ratio, 0.71; 95% CI, 0.58 to 0.86). When comparing competing causes of failure (breast cancer recurrence and deaths before breast cancer recurrence), p+T was far superior in controlling breast cancer recurrence (P = .0003), but the improvement was seen mainly in soft tissue sites. Conversely, patients in the p+T group were more likely to die before a breast cancer recurrence (P = .03). Conclusion: This trial demonstrates that significant treatment benefits continue to be observed in older patients treated for 1 year with p+T. Despite issues relating to competing causes of failure, older breast cancer patients can benefit from treatment and should be considered for trials of adjuvant systemic therapy.

Original languageEnglish
Pages (from-to)4517-4523
Number of pages7
JournalJournal of Clinical Oncology
Volume21
Issue number24
DOIs
Publication statusPublished - Dec 15 2003

Fingerprint

Breast Neoplasms
Recurrence
Therapeutics
Simple Mastectomy
Tamoxifen
Prednisone
Life Expectancy
Disease-Free Survival
Lymph Nodes
Survival
Incidence
Population

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Adjuvant endocrine therapy compared with no systemic therapy for elderly women with early breast cancer : 21-Year results of International Breast Cancer Study Group Trial IV. / Crivellari, Diana; Price, Karen; Gelber, Richard D.; Castiglione-Gertsch, Monica; Rudenstam, Carl Magnus; Lindtner, Jurij; Fey, Martin F.; Senn, Hans Jörg; Coates, Alan S.; Collins, John; Goldhirsch, Aron.

In: Journal of Clinical Oncology, Vol. 21, No. 24, 15.12.2003, p. 4517-4523.

Research output: Contribution to journalArticle

Crivellari, D, Price, K, Gelber, RD, Castiglione-Gertsch, M, Rudenstam, CM, Lindtner, J, Fey, MF, Senn, HJ, Coates, AS, Collins, J & Goldhirsch, A 2003, 'Adjuvant endocrine therapy compared with no systemic therapy for elderly women with early breast cancer: 21-Year results of International Breast Cancer Study Group Trial IV', Journal of Clinical Oncology, vol. 21, no. 24, pp. 4517-4523. https://doi.org/10.1200/JCO.2003.03.559
Crivellari, Diana ; Price, Karen ; Gelber, Richard D. ; Castiglione-Gertsch, Monica ; Rudenstam, Carl Magnus ; Lindtner, Jurij ; Fey, Martin F. ; Senn, Hans Jörg ; Coates, Alan S. ; Collins, John ; Goldhirsch, Aron. / Adjuvant endocrine therapy compared with no systemic therapy for elderly women with early breast cancer : 21-Year results of International Breast Cancer Study Group Trial IV. In: Journal of Clinical Oncology. 2003 ; Vol. 21, No. 24. pp. 4517-4523.
@article{3d63418cf080460497aada17c36da2d2,
title = "Adjuvant endocrine therapy compared with no systemic therapy for elderly women with early breast cancer: 21-Year results of International Breast Cancer Study Group Trial IV",
abstract = "Purpose: Increasing numbers of older women are affected by early breast cancer, because of prolonged life expectancy and the increasing incidence of breast cancer with age. The role of adjuvant therapy for this population is still a matter of debate. We reviewed the long-term outcome of a mature trial comparing endocrine treatment versus no adjuvant therapy in older women with node-positive breast cancer. Patients and Methods: From 1978 to 1981, 349 women 66 to 80 years of age with pathologically involved lymph nodes after total mastectomy and axillary clearance were randomly assigned to receive 12 months of adjuvant tamoxifen plus low-dose prednisone (p+T) or no adjuvant therapy. Three hundred twenty patients were eligible. Results: At 21 years' median follow-up, 1 year of p+T significantly prolonged disease-free survival (DFS; P = .003) and overall survival (P = .05; 15-year DFS, 10{\%} ± 3{\%} v 19{\%} ± 3{\%}; hazard ratio, 0.71; 95{\%} CI, 0.58 to 0.86). When comparing competing causes of failure (breast cancer recurrence and deaths before breast cancer recurrence), p+T was far superior in controlling breast cancer recurrence (P = .0003), but the improvement was seen mainly in soft tissue sites. Conversely, patients in the p+T group were more likely to die before a breast cancer recurrence (P = .03). Conclusion: This trial demonstrates that significant treatment benefits continue to be observed in older patients treated for 1 year with p+T. Despite issues relating to competing causes of failure, older breast cancer patients can benefit from treatment and should be considered for trials of adjuvant systemic therapy.",
author = "Diana Crivellari and Karen Price and Gelber, {Richard D.} and Monica Castiglione-Gertsch and Rudenstam, {Carl Magnus} and Jurij Lindtner and Fey, {Martin F.} and Senn, {Hans J{\"o}rg} and Coates, {Alan S.} and John Collins and Aron Goldhirsch",
year = "2003",
month = "12",
day = "15",
doi = "10.1200/JCO.2003.03.559",
language = "English",
volume = "21",
pages = "4517--4523",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "24",

}

TY - JOUR

T1 - Adjuvant endocrine therapy compared with no systemic therapy for elderly women with early breast cancer

T2 - 21-Year results of International Breast Cancer Study Group Trial IV

AU - Crivellari, Diana

AU - Price, Karen

AU - Gelber, Richard D.

AU - Castiglione-Gertsch, Monica

AU - Rudenstam, Carl Magnus

AU - Lindtner, Jurij

AU - Fey, Martin F.

AU - Senn, Hans Jörg

AU - Coates, Alan S.

AU - Collins, John

AU - Goldhirsch, Aron

PY - 2003/12/15

Y1 - 2003/12/15

N2 - Purpose: Increasing numbers of older women are affected by early breast cancer, because of prolonged life expectancy and the increasing incidence of breast cancer with age. The role of adjuvant therapy for this population is still a matter of debate. We reviewed the long-term outcome of a mature trial comparing endocrine treatment versus no adjuvant therapy in older women with node-positive breast cancer. Patients and Methods: From 1978 to 1981, 349 women 66 to 80 years of age with pathologically involved lymph nodes after total mastectomy and axillary clearance were randomly assigned to receive 12 months of adjuvant tamoxifen plus low-dose prednisone (p+T) or no adjuvant therapy. Three hundred twenty patients were eligible. Results: At 21 years' median follow-up, 1 year of p+T significantly prolonged disease-free survival (DFS; P = .003) and overall survival (P = .05; 15-year DFS, 10% ± 3% v 19% ± 3%; hazard ratio, 0.71; 95% CI, 0.58 to 0.86). When comparing competing causes of failure (breast cancer recurrence and deaths before breast cancer recurrence), p+T was far superior in controlling breast cancer recurrence (P = .0003), but the improvement was seen mainly in soft tissue sites. Conversely, patients in the p+T group were more likely to die before a breast cancer recurrence (P = .03). Conclusion: This trial demonstrates that significant treatment benefits continue to be observed in older patients treated for 1 year with p+T. Despite issues relating to competing causes of failure, older breast cancer patients can benefit from treatment and should be considered for trials of adjuvant systemic therapy.

AB - Purpose: Increasing numbers of older women are affected by early breast cancer, because of prolonged life expectancy and the increasing incidence of breast cancer with age. The role of adjuvant therapy for this population is still a matter of debate. We reviewed the long-term outcome of a mature trial comparing endocrine treatment versus no adjuvant therapy in older women with node-positive breast cancer. Patients and Methods: From 1978 to 1981, 349 women 66 to 80 years of age with pathologically involved lymph nodes after total mastectomy and axillary clearance were randomly assigned to receive 12 months of adjuvant tamoxifen plus low-dose prednisone (p+T) or no adjuvant therapy. Three hundred twenty patients were eligible. Results: At 21 years' median follow-up, 1 year of p+T significantly prolonged disease-free survival (DFS; P = .003) and overall survival (P = .05; 15-year DFS, 10% ± 3% v 19% ± 3%; hazard ratio, 0.71; 95% CI, 0.58 to 0.86). When comparing competing causes of failure (breast cancer recurrence and deaths before breast cancer recurrence), p+T was far superior in controlling breast cancer recurrence (P = .0003), but the improvement was seen mainly in soft tissue sites. Conversely, patients in the p+T group were more likely to die before a breast cancer recurrence (P = .03). Conclusion: This trial demonstrates that significant treatment benefits continue to be observed in older patients treated for 1 year with p+T. Despite issues relating to competing causes of failure, older breast cancer patients can benefit from treatment and should be considered for trials of adjuvant systemic therapy.

UR - http://www.scopus.com/inward/record.url?scp=1542753651&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1542753651&partnerID=8YFLogxK

U2 - 10.1200/JCO.2003.03.559

DO - 10.1200/JCO.2003.03.559

M3 - Article

C2 - 14673038

AN - SCOPUS:1542753651

VL - 21

SP - 4517

EP - 4523

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 24

ER -